Bringing clarity and precision to the cell-free space by introducing exozymes
eXoZymes Inc. (NASDAQ: EXOZ) is featured as the cover story in the April 2025 issue of GEN Biotechnology, introducing the scientific definition of 'exozymes' to clarify the cell-free biomanufacturing field. The peer-reviewed Open Access paper titled 'Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space' aims to distinguish cell-free biomanufacturing from other cell-free technologies.
The paper, co-authored by experts from institutions including NREL, UCLA, Caltech, and University of Colorado Boulder, defines exozymes as industrial biomanufacturing methods that produce chemicals without using living cells. The terms 'exozymes' and 'exozyme systems' are introduced to facilitate better understanding among investors, scientists, and the public, with no trademarks filed to ensure free usage by the scientific community.
eXoZymes Inc. (NASDAQ: EXOZ) è protagonista della copertina del numero di aprile 2025 di GEN Biotechnology, presentando la definizione scientifica di "exozymes" per chiarire il campo della bioproduzione senza cellule. L'articolo peer-reviewed ad accesso aperto intitolato "Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space" ha l'obiettivo di distinguere la bioproduzione senza cellule da altre tecnologie senza cellule.
L'articolo, co-scritto da esperti di istituzioni come NREL, UCLA, Caltech e University of Colorado Boulder, definisce gli exozymes come metodi industriali di bioproduzione che producono sostanze chimiche senza utilizzare cellule viventi. I termini "exozymes" e "sistemi exozymes" sono stati introdotti per facilitare una migliore comprensione tra investitori, scienziati e pubblico, senza marchi registrati per garantire l'uso libero da parte della comunità scientifica.
eXoZymes Inc. (NASDAQ: EXOZ) es la historia principal de la portada de la edición de abril de 2025 de GEN Biotechnology, donde se introduce la definición científica de "exozymes" para aclarar el campo de la biomanufactura sin células. El artículo revisado por pares y de acceso abierto titulado "Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space" tiene como objetivo distinguir la biomanufactura sin células de otras tecnologías sin células.
El artículo, coautoría de expertos de instituciones como NREL, UCLA, Caltech y la Universidad de Colorado Boulder, define los exozymes como métodos industriales de biomanufactura que producen químicos sin usar células vivas. Los términos "exozymes" y "sistemas exozymes" se introducen para facilitar una mejor comprensión entre inversores, científicos y el público, sin marcas registradas para garantizar el uso libre por parte de la comunidad científica.
eXoZymes Inc. (NASDAQ: EXOZ)가 2025년 4월호 GEN Biotechnology 표지 기사로 소개되었으며, 세포 없는 생물제조 분야를 명확히 하기 위해 'exozymes'의 과학적 정의를 제시합니다. 동료 검토를 거친 오픈 액세스 논문 "Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space"는 세포 없는 생물제조를 다른 세포 없는 기술과 구분하는 것을 목표로 합니다.
이 논문은 NREL, UCLA, Caltech, 콜로라도 대학교 볼더 캠퍼스 등 기관의 전문가들이 공동 저술했으며, exozymes를 살아있는 세포를 사용하지 않고 화학물질을 생산하는 산업용 생물제조 방법으로 정의합니다. 'exozymes'와 'exozyme 시스템'이라는 용어를 도입하여 투자자, 과학자, 대중이 더 잘 이해할 수 있도록 했으며, 과학계의 자유로운 사용을 위해 상표 등록은 하지 않았습니다.
eXoZymes Inc. (NASDAQ : EXOZ) est à la une du numéro d’avril 2025 de GEN Biotechnology, présentant la définition scientifique des « exozymes » afin de clarifier le domaine de la bioproduction sans cellules. L’article en accès libre et évalué par des pairs intitulé « Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space » vise à distinguer la bioproduction sans cellules des autres technologies sans cellules.
L’article, coécrit par des experts d’institutions telles que NREL, UCLA, Caltech et l’Université du Colorado à Boulder, définit les exozymes comme des méthodes industrielles de bioproduction qui fabriquent des produits chimiques sans utiliser de cellules vivantes. Les termes « exozymes » et « systèmes exozymes » sont introduits pour faciliter une meilleure compréhension auprès des investisseurs, des scientifiques et du grand public, sans dépôt de marque afin d’assurer une utilisation libre par la communauté scientifique.
eXoZymes Inc. (NASDAQ: EXOZ) ist die Titelgeschichte der April-Ausgabe 2025 von GEN Biotechnology und führt die wissenschaftliche Definition von „Exozymes“ ein, um das Feld der zellfreien Bioproduktion zu klären. Das peer-reviewte Open-Access-Papier mit dem Titel „Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space“ zielt darauf ab, die zellfreie Bioproduktion von anderen zellfreien Technologien abzugrenzen.
Das Papier, verfasst von Experten renommierter Institutionen wie NREL, UCLA, Caltech und der University of Colorado Boulder, definiert Exozymes als industrielle biotechnologische Herstellungsverfahren, die Chemikalien ohne lebende Zellen produzieren. Die Begriffe „Exozymes“ und „Exozyme-Systeme“ wurden eingeführt, um Investoren, Wissenschaftlern und der Öffentlichkeit ein besseres Verständnis zu ermöglichen, wobei keine Markenrechte angemeldet wurden, um die freie Nutzung durch die wissenschaftliche Gemeinschaft sicherzustellen.
- Technology enables cost-effective and scalable biomanufacturing compared to traditional fermentation methods
- Platform shows innovative potential in drug development space
- Publication in peer-reviewed journal validates technology approach
- None.
Scientific definition of exozymes featured as cover story in GEN Biotechnology, freely available as an Open Access paper
The author team introduces the terms ‘exozymes’ to bring clarity to the rapidly evolving field of cell-free biomanufacturing—a biomanufacturing method to produce chemicals without relying on living cells like bacteria or yeast
The paper features co-authors from multiple institutions such as The National Renewable Laboratory (NREL), UCLA, Caltech, University of Colorado Boulder, Sepia Biosciences, as well as the venture studio, Ferment
The authors intend the terms to be freely available for use by the broader scientific community, and no trademarks have been filed
Monrovia, CA, April 21, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - is featured as the cover story in the April issue of the peer-reviewed journal, GEN Biotechnology.
Dr. Tyler Korman, co-founder and VP of Research at eXoZymes, is excited about the 'exozymes' cover story in GEN Biotechnology, which is freely available as an Open Access paper
The Perspective paper called “Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space” focuses on providing a scientific definition of 'exozymes' to alleviate confusion surrounding use of the phrase 'cell-free' with an emphasis on its use in biomanufacturing. While the most well-known and successful applications of ‘cell-free’ technologies include next-generation sequencing-based diagnostics utilizing cell-free DNA/RNA (cfDNA/RNA), cell-free protein synthesis (CFPS, among others), these technologies, their operational mechanisms, processes, and final products differ significantly from ‘cell-free biomanufacturing’.
Member of the Strategic Advisory Board at Codexis and eXoZymes Board Member, Dr. Jim Lalonde, elaborates, “As a concept, exozymes unlocks the increased leverage from the evolution of the biotechnology tool stack and its synergy with AI. I think about those technologies amplifying the inherent properties of enzymes to enable them to be cost-effective and scalable in ways that fermentation simply cannot match. In my mind, this is a massive unlock for biotechnology and one of the reasons the "Exozyme Era" has arrived.”
Dr. Kevin Davies, Executive Editor of GEN Biotechnology, adds, "The team at eXoZymes caught our eye recently with its very well-orchestrated rebranding but, more importantly, the innovative potential this platform represents in the drug development space. We think the Perspective that the company has just published in GEN Biotechnology after peer review has far-reaching value for the biotech community, providing rich historical context on the breadth and in some cases, misconceptions of what cell-free research entails as well as advocating for new terminology. This paper could have been published in any number of high-visibility journals; we're grateful that the eXoZymes team chose GEN Biotechnology to validate and disseminate this work."
Dr. Tyler Korman, co-founder and VP of Research at eXoZymes states, “By introducing exozymes as a common terminology, we enable investors, the scientific community, and the laymen to understand that when we speak about an exozyme or exozyme system, we're talking about industrial biomanufacturing. We thank GEN Biotechnology for the help in doing this and we hope that with this new terminology we can all coalesce around a common language to push the field forward in the future.”
The author team introduces the terms ‘exozymes’ and ‘exozyme systems’ to bring clarity to the rapidly evolving field of cell-free biomanufacturing—a method of producing chemicals without relying on living cells like bacteria or yeast. By formally adopting the terms exozyme and exozyme system, the authors aim to accelerate innovation, streamline partnerships, and make it easier to fund and regulate the next generation of biomanufacturing.
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to engineer, control and optimize nature’s own natural processes to produce chemical compounds, enabling the company’s partners to replace traditional chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.
Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced “exozymes” as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Learn more on exozymes.com.
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of eXoZymes’ quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
Attachment
FAQ
What is the significance of EXOZ's exozymes paper in GEN Biotechnology?
How does EXOZ's exozyme technology differ from traditional cell-free methods?
What institutions collaborated on EXOZ's exozyme research paper?
What are the potential applications of EXOZ's exozyme technology?
